Highlight
– Early intravenous immunoglobulin (IVIg) treatment within the first year of anti-IgLON5 disease onset is associated with significantly lower long-term disability and mortality.
– Early immunotherapy overall improves survival and functional outcomes compared to delayed or no treatment.
– Rituximab and other immunotherapies initiated early did not demonstrate the same survival benefit as IVIg in this cohort.
– Anti-IgLON5 disease deaths are predominantly disease-related, underscoring the need for effective early immunotherapy.
